Roanoke, VA, United States
Roanoke, VA, United States

Time filter

Source Type

News Article | October 28, 2016
Site: www.prweb.com

The National Center for Healthcare Leadership (NCHL) has identified 19 leading “BOLD” healthcare organizations that are front-runners in using evidence-based leadership development practices to improve health and healthcare in their communities. These organizations ranked highest in NCHL’s 2016 National Health Leadership Survey, which was sponsored by Cielo Healthcare. BOLD—Best Organizations for Leadership Development—is NCHL’s signature platform promoting sound leadership development practices as a critically important responsibility for healthcare-providing organizations and their senior leaders. “BOLD helps identify, celebrate, and disseminate leadership development practices that can benefit other healthcare organizations,” NCHL President Tim Rice said. “We congratulate those BOLD organizations for their innovation and commitment to leadership development.” The ten highest ranking BOLD organizations are: Banner Health (Phoenix), Carilion Clinic (Roanoke, VA), Carolinas HealthCare System (Charlotte, VA), Duke Regional Hospital (Durham, NC), Henry Ford Health System (Detroit, MI), Memorial Health System (Springfield, IL), Northwell Health (Great Neck, NY), Penn Medicine (Philadelphia, PA), Stanford Children's Health/Lucile Packard Children’s Hospital Stanford (Palo Alto, CA), and Tenet Healthcare (Dallas, TX). Nine organizations that are recognized as Organizations of Distinction are: Aurora Health Care (Milwaukee, WI), BayCare Health System (Tampa, FL), Cleveland Clinic (Cleveland, OH), Cone Health (Greensboro, NC), Deaconess Health System (Evansville, IN), Magee Rehabilitation Hospital (Philadelphia, PA), Palmetto Health (Columbia, SC), Renown Health (Reno, NV), and Yale New Haven Hospital (New Haven, CT). “BOLD honors health systems for their commitment to leadership development,” Cielo Healthcare President Jill Schwieters said. “There is no more important work than developing great leaders to serve, and BOLD illuminates approaches that are most effective.” NCHL will recognize BOLD awardees and Organizations of Distinction at its 2016 Human Capital Investment Conference on November 15-16 at The Ritz-Carlton Chicago. On November 15, industry leaders will explore to ways to create organizational culture that is innovative, collaborative, and resilient. That evening, Christine Cassel, MD, planning dean of Kaiser Permanente School of Medicine, will be honored as the 2016 recipient of the Gail L. Warden Leadership Excellence Award. The next day will showcase the leadership best practices of leading healthcare organizations, such as attracting and selecting leaders, talent management, coaching, diversity leadership, and succession planning. ABOUT THE NATIONAL CENTER FOR HEALTHCARE LEADERSHIP The National Center for Healthcare Leadership (NCHL), a Chicago-based not-for-profit organization, is an industry catalyst to ensure the availability of accountable and transformational healthcare leadership for the 21st century. Its vision is to improve the health of the public through leadership and organizational excellence. For more information please visit NCHL’s website at nchl.org. ABOUT CIELO HEALTHCARE Cielo Healthcare is the world’s leading provider of strategic Recruitment Process Outsourcing solutions for the healthcare industry. Cielo Healthcare leverages its deep provider expertise, customized, innovative solutions and entrepreneurial agility to help clients achieve sustained people advantage and outstanding organizational outcomes. Cielo Healthcare knows talent is rising, and with it, healthcare’s opportunity to rise above. For more information, visit cielohealthcare.com.


News Article | February 6, 2017
Site: globenewswire.com

ROANOKE, Va., Feb. 06, 2017 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ:RGCO) announces election of Directors at its shareholders meeting held on February 6, 2017. Shareholders approved the election of Nancy Howell Agee, President and CEO, Carilion Clinic, J. Allen Layman, Private Investor, and Raymond D. Smoot, Jr., Senior Fellow, Virginia Tech Foundation, Inc. for three-year terms. Shareholders also ratified the appointment of Brown Edwards and Company L.L.P. as auditors for fiscal 2017 and approved the RGC Resources, Inc. Restricted Stock Plan. At a meeting of the Board of Directors, following the annual shareholders meeting, John B. Williamson, III was elected Chairman of the Board and John S. D’Orazio was elected President and CEO of RGC Resources, Inc. The following senior officers were also elected: Paul W. Nester, Vice President, Secretary, Treasurer and CFO, Robert L. Wells, II, Vice President, Information Technology, and Carl J. Shockley, Vice President of Operations, Roanoke Gas Company. RGC Resources, Inc. provides energy and related products and services to approximately 60,000 customers in Virginia through its operating subsidiaries including Roanoke Gas Company and RGC Midstream, LLC. From time to time, the Company may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that a variety of factors could cause the Company’s actual results and experience to differ materially from the anticipated results or other expectations expressed in the Company’s forward-looking statements. RGC Resources, Inc. stock is traded on the Nasdaq National Market with the trading symbol RGCO.


News Article | December 12, 2016
Site: www.eurekalert.org

The University of Virginia-Virginia Tech Carilion Neuroscience Research Collaboration today announced more than a half-million dollars in grant funding will be awarded to nine research teams to tackle pressing problems in brain development and function in health and disease. Investigators received the awards through a competitive review process and were notified this week by Michael J. Friedlander, vice president for health sciences and technology and professor at Virginia Tech, where he is also the executive director of the Virginia Tech Carilion Research Institute and the senior dean for research at the Virginia Tech Carilion School of Medicine; and Margaret Shupnik, senior associate dean for research and a professor at the University of Virginia School of Medicine, where she is also the Gerald D. Aurbach Professor of Endocrinology. "We are planting seeds that will bring additional research funding to the commonwealth from government agencies, private organizations, industry, and foundations," said Virginia Tech President Tim Sands. "We continue to pursue partnerships with people and organizations who want to join us in solving some of the most pressing problems in health care." The leadership of the University of Virginia School of Medicine, Carilion Clinic, Virginia Tech, and the Virginia Tech Carilion Research Institute provided financing for the program and issued an open call for proposals with a submission deadline of Oct. 10 through the University of Virginia - Virginia Tech Carilion Neuroscience Research Collaboration. In all, $550,000 will be awarded to nine projects with each receiving between $50,000 and $70,000. "We are taking full advantage of the combined talent of our faculty and encouraging lasting brain research collaborations between the University of Virginia and Virginia Tech Carilion," Friedlander said. "The pilot funding will serve as a catalyst to form new teams to tackle important questions, perform transformative work, obtain new extramural research funding in neuroscience for each of the partner institutions, and to develop new applications." Organizers believe that the dialogues and the new collaborations stimulated by the program ultimately will generate significant, meaningful knowledge to benefit society, Shupnik said. "The proposals speak to the scientific strength at our institutions and the synergies that these collaborations will create: studies of the causes of and means of diagnosing neurological diseases; new methods for understanding brain development, normal function, and dysfunction; models of neural circuitry; and potential interventions to restore function to the diseased nervous system," Shupnik said. Carilion Clinic President and CEO Nancy Howell Agee said, "Research leads to better health care outcomes and better lives for our patients." "These projects will provide a strong foundation for future research collaborations and funding opportunities, with the ultimate goal of benefiting our patients," Agee added. New strategies for treating Rett syndrome in children; The development of the blood supply to the brain; The mechanical forces of injuries leading to concussions; The use of ultrasound to modulate critical chemical neurotransmitters in the human brain to affect behavior; Development of new therapeutics for multiple sclerosis; The role of breast cancer genes in brain function and development; The relationship between seizures and microcephaly; The University of Virginia - Virginia Tech Carilion Neuroscience Research Collaboration has been several years in the making, Friedlander said. "From the beginning it was clear that there was enormous talent in brain research in the commonwealth with distinct areas of excellence but little in the way of cross-institutional collaborations," said Friedlander, who arrived as the executive director at Virginia Tech Carilion Research Institute in 2010 and began recruiting 15 leading brain research teams to Roanoke, Virginia. Friedlander worked closely with leading neuroscientists at several universities across the state, who went on to develop ties and began planning a strategy to transform Virginia into "The Brain State" -- a hub of scientific efforts and leading technological innovation to understand brain function and to develop new paradigms for diagnostics and treatments for brain-related disorders. Meanwhile, the state's political leadership expressed support for collaborative efforts between the state's universities, which resulted in a statewide Virginia Neuroscience Initiative, coordinated by the Virginia Biosciences Health Research Corp. In addition, teams of neuroscientists at various universities and health systems in Virginia identified opportunities to partner for major breakthroughs and new funding strategies. The University of Virginia School of Medicine, Virginia Tech, and Carilion Clinic neuroscience teams hosted each other and shared their work at multiple meetings at the Virginia Tech Carilion Research Institute in Roanoke and at the University of Virginia School of Medicine in Charlottesville. "It was apparent from the outset that the enthusiasm for collaborating and energy for developing new approaches to some of the most important problems in neuroscience between the University of Virginia and Virginia Tech Carilion neuroscientists were extremely high," Friedlander said. The teams decided they would begin a series of collaborations building on their complementary strengths and mutual interests, identifying focused topics for advanced inquiry. After the competitive review process of 24 proposals involving more than 50 investigators, nine proposals were selected for funding: Co-principal investigators Andrea Bertke, an assistant professor of population health sciences with the Virginia-Maryland College of Veterinary Medicine; and Anna Cliffe, an assistant professor of microbiology, immunology, and cancer biology at the University of Virginia School of Medicine: Chromatin Composition of Latent HSV-1 and HSV-2; Co-principal investigators Sanchita Bhatnagar, an assistant professor of biochemistry and molecular genetics at the University of Virginia; Alexei Morozov, an assistant professor at the Virginia Tech Carilion Research Institute and the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences; Michael McConnell, an assistant professor of biochemistry and molecular genetics; and Mark Beenhakker, an assistant professor of pharmacology, both of the University of Virginia: Pharmacological Reactivation of Inactive X-linked MECP2 for Rett Syndrome Therapeutics; Co-principal investigators John Chappell, an assistant professor at the Virginia Tech Carilion Research Institute and the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences; Shayn Peirce-Cottler, a professor of biomedical engineering at the University of Virginia: Computational and Experimental Modeling of Blood Vessel Growth and Vascular Pericyte Investment in the Developing Germinal Matrix; Co-principal investigators Stefan Duma, the Harry C. Wyatt Professor at the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences and director of the Virginia Tech Institute for Critical Technologies and Applied Science; Steven Rowson, an assistant professor at the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences; and Matthew Panzer, an assistant professor of mechanical and aerospace engineering at the University of Virginia: Brain Strain Patterns Associated with Concussion Injury; Co-principal investigators Jeff Elias, a professor of neurosurgery at the University of Virginia School of Medicine; Read Montague, the Virginia Tech Carilion Vernon Mountcastle Research Professor at the Virginia Tech Carilion Research Institute and professor of physics at Virginia Tech; and Mark Witcher, an assistant professor of neurosurgery at the Virginia Tech Carilion School of Medicine and Carilion Clinic: Impact of Cognitive and Ultrasound Stimulated Serotonin and Dopamine Release in Human and Swine Striatum; Co-principal investigators Alban Gaultier, an assistant professor of neuroscience at the University of Virginia; Kevin Lynch, a professor of pharmacology at the University of Virginia; and Webster Santos, an associate professor of bioorganic and medicinal chemistry in the Virginia Tech College of Science: Sphingosine Kinase Inhibitors and Multiple Sclerosis; Co-principal investigators Deborah Kelly, an assistant professor at the Virginia Tech Carilion Research Institute and the Department of Biological Sciences at Virginia Tech; and Mark Yeager, a professor of molecular physiology and biological physics, and of cardiovascular medicine at the University of Virginia School of Medicine: Decoding the Role of BRCA1 in Brain Cells using High-Resolution Cryo-EM; Co-principal investigators Samy Lamouille, a research assistant professor at the Virginia Tech Carilion Research Institute; and Benjamin Purow, a professor of neurology at the University of Virginia: Disruption of Cx43-mediated Regulation of Microtubules to Eradicate Glioma Stem Cells in Glioblastoma Treatment; Co-principal investigators Konark Mukherjee, an assistant professor at the Virginia Tech Carilion Research Institute and the Virginia Tech Department of Biological Sciences; and Howard Goodkin, a professor of neurology and pediatrics at the University of Virginia: Contribution of Early Epileptiform Activity to Secondary Microencephaly in CASK(+/-) Mice. Additional resources are available at Virginia Tech News.


LYON, France & NEW YORK--(BUSINESS WIRE)--The MEDICREA Group (Alternext Paris: FR0004178572 - ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, today announced that it will host a Key Opinion Leader breakfast in New York City for investors focused on advances in the personalized spine market at 8:00 am Eastern Time on Thursday, December 15, 2016. The meeting will feature keynote presentations by spine surgeon KOLs Nicholas Qandah, DO, from the Mohawk Valley Health System, and Themistocles Protopsaltis, MD, from NYU Langone Medical Center, Bellevue Hospital, who will provide an overview of the complex spine market and discuss current and novel approaches to treating complex spinal conditions. Members of the Medicrea management team will provide an overview of the Company’s UNiD™ personalized spinal technology platform of analytical services and patient-specific implants for the complex spine market, which received the first ever FDA Clearance for a personalized spinal treatment modality. Dr. Nicholas Qandah is a complex spine specialist and the Director of Neurosurgery at the Mohawk Valley Health System in New Hartford, NY. Dr. Qandah was previously the Director of the Complex Spine Program for Neurosurgery and an Assistant Professor of Neurosurgery for the Residency Program at Virginia Tech Carilion Clinic in Roanoke, VA. In addition to general neurosurgery, Dr. Qandah treats patients with back and neck pain, degenerative disc disease, spinal stenosis, and herniated discs. He has special interest and expertise in minimally invasive spine surgery, complex spine surgery, and surgery for scoliosis. Dr. Qandah is a Fellow of the American College of Osteopathic Surgeons and a member of the Association for Collaborative Spine Research. Dr. Qandah completed his Neurosurgical Residency training at the Virginia Tech Carilion Clinic and was subsequently awarded the AO Complex Spine Fellowship in Orthopedics and Neurosurgery at the prestigious Harborview Medical Center at the University of Washington in Seattle, WA. Dr. Themistocles Protopsaltis is an orthopedic spine surgeon at NYU Langone Medical Center and the Hospital for Joint Diseases. He serves as Director of Adult Spinal Deformity Surgery and Director of the Orthopaedic Spine Service at Bellevue Hospital Center in New York, NY. He is also an Assistant Professor in the Department of Orthopedic Surgery at NYU School of Medicine. Dr. Protopsaltis is board certified in orthopedic surgery and is actively involved in many research areas. Some of his interests include cervical and thoracolumbar spinal deformity, cervical spondylotic myelopathy surgical outcomes, and proximal junctional kyphosis avoidance in adult scoliosis patients. He is a member of the International Spine Study Group, comprised of leading physicians from multiple academic centers studying cervical and thoracolumbar spinal deformity surgery. He is also a fellow of the American Academy of Orthopaedic Surgeons. Dr. Protopsaltis earned his medical degree at the Columbia University College of Physicians and Surgeons and completed his orthopedic surgery residency at New York Presbyterian Hospital. He has completed a spine surgery fellowship at NYU Langone Hospital for Joint Diseases. The event is intended for investors, analysts, investment bankers, and business development professionals only. If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com to reserve a place. A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20161215/reg.jsp and within the Investors section of the Company’s website at www.medicrea.com. MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, MEDICREA is an SME with 150 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient- specific implants. By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, MEDICREA is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R. For further information, please visit: medicrea.com.


Sawaya G.F.,University of California at San Francisco | Kulasingam S.,University of Minnesota | Denberg T.D.,Carilion Clinic | Qaseem A.,The American College
Annals of Internal Medicine | Year: 2015

Description: The purpose of this best practice advice article is to describe the indications for screening for cervical cancer in asymptomatic, average-risk women aged 21 years or older. Methods: The evidence reviewed in this work is a distillation of relevant publications (including systematic reviews) used to support current guidelines. Best Practice Advice 1: Clinicians should not screen averagerisk women younger than 21 years for cervical cancer. Best Practice Advice 2: Clinicians should start screening average-risk women for cervical cancer at age 21 years once every 3 years with cytology (cytologic tests without human papillomavirus [HPV] tests). Best Practice Advice 3: Clinicians should not screen averagerisk women for cervical cancer with cytology more often than once every 3 years. Best Practice Advice 4: Clinicians may use a combination of cytology and HPV testing once every 5 years in average-risk women aged 30 years or older who prefer screening less often than every 3 years. Best Practice Advice 5: Clinicians should not perform HPV testing in average-risk women younger than 30 years. Best Practice Advice 6: Clinicians should stop screening average-risk women older than 65 years for cervical cancer if they have had 3 consecutive negative cytology results or 2 consecutive negative cytology plus HPV test results within 10 years, with the most recent test performed within 5 years. Best Practice Advice 7: Clinicians should not screen averagerisk women of any age for cervical cancer if they have had a hysterectomy with removal of the cervix. © 2015 American College of Physicians.


MELVILLE, NY--(Marketwired - November 01, 2016) - North American Partners in Anesthesia (NAPA), one of the largest single-specialty anesthesia and perioperative management companies in the United States, announced today that Rafael Cartagena, MD, Regional Director and Mr. Peter Doerner, Executive Vice President & Chief Development Officer, will be featured speakers at the Becker's Hospital Review 5th Annual CEO + CFO Roundtable. In addition, Steven Hattamer, MD, Chief of Anesthesia will serve on an educational panel. NAPA will also be hosting an exclusive invitation-only advisory roundtable at the event on the topic, "The Presidential Election and its Impact on the Future Direction of Healthcare Reform." The event will take place November 7-9, 2016 at the Swissotel in Chicago, IL. Dr. Cartagena and Mr. Doerner are scheduled to speak on Tuesday, November 8 at 1:35pm. Their presentation, entitled, "Improving OR Efficiencies: How Technology-Driven Solutions Drive Measurable Results" will focus on the adoption of technology and its ability to drive cultural transformation and process improvements and operational efficiencies in the OR suite. Key case studies will be included to demonstrate how the reimagined OR and technological integration have encouraged multidisciplinary collaboration while improving quality of care, clinical outcomes and the patient experience. "High-functioning operating rooms are paramount to a hospital's financial sustainability," said Mr. Doerner. "As such, it is important to define clear metrics that align with the organization's objectives. With the utilization of new technological capabilities, key stakeholders can gain access to critical data leading to more informed decisions on one of the hospital's biggest revenue generators and cost centers -- the OR." Doerner is a proven senior Healthcare executive with over 25 years of leadership experience in hospitals and other healthcare facilities. He has created significant solutions for healthcare organizations focused on continuous operational, fiscal, and clinical improvement. Rafael Cartagena, MD is a Diplomate of the American Board of Anesthesiology. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA. Dr. Cartagena completed his residency at the Hospital of Pennsylvania in Philadelphia, PA. In addition, Steven Hattamer, MD, will also be participating in a panel discussion at the same event entitled, "The Development of Physician Leaders: How to Retain and Champion Great Physician Leaders" on Friday, November 9 at 1:40pm. The panel will explore how hospitals can identify, grow and best utilize their physician leaders. The esteemed panel will answer questions regarding how to structure physician leadership as a manageable responsibility so physicians can maintain their practice and work-life balance as well as how physician leaders can help their colleagues avoid or recover from burnout. The panel will also discuss the importance of including physician leaders in crucial conversations on cost and how hospitals can best utilize their physicians as a retention tool. The other panelists include Patrice M. Weiss, MD, Executive Vice President & Chief Medical Officer, Carilion Clinic; Howard Drenth, President & Chief Executive Officer, Florida Hospital Medical Group; Lydia Ostermeier, Vice President, Senior Executive Search, B.E. Smith; and Steven Airhart, Chief Executive Officer, Hartgrove Behavioral Health System. According to Dr. Hattamer, "It's just not enough for physicians just to save lives anymore. To have a meaningful impact on the profession, they must come out from behind the drapes and engage with the new iteration of healthcare." Steven Hattamer, MD is a Diplomate of the American Board of Anesthesiology, American Academy of Pain Management and National Board of Medical Examiners. He received his medical degree from the University of Kansas School of Medicine. Dr. Hattamer completed his anesthesia residency at Dartmouth-Hitchcock Medical Center in Lebanon, NH. He sits on the Board of Directors for the American Society of Anesthesiologists and Preferred Physicians Mutual. In addition, Dr. Hattamer serves as Chair for the American Medical Association's Anesthesia Section Council. Becker's Hospital Review 5th Annual CEO Roundtable + CFO Roundtable focuses on core issues, opportunities and strategy for the hospital and health system CEO and CFO audience. 100+ hospital and health system speakers will be presenting at the event regarding best strategies, financial opportunities and IT developments that will benefit hospitals in 2017. About North American Partners in Anesthesia As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. In three decades, NAPA has grown to become one of the nation's leading single-specialty anesthesia and perioperative management companies, serving more than one million patients annually in more than 200 healthcare facilities throughout the Northeast, Mid-Atlantic, Midwest and Southeast. Our highly skilled teams of clinicians participate in groundbreaking leadership development and customer service training programs to deliver optimal results to patients, surgeons, healthcare administrators and staff. Through our exceptional perioperative leadership, research, innovations and state-of-the-art technologies, NAPA offers real solutions driven by evidence-based outcomes to dramatically accelerate operational efficiencies, increase satisfaction ratings and enhance safety and profitability. For more information, please visit NAPAanesthesia.com. The following files are available for download:


Qaseem A.,The American College | Dallas P.,Virginia Polytechnic Institute and State University | Forciea M.A.,University of Pennsylvania | Starkey M.,The American College | Denberg T.D.,Carilion Clinic
Annals of Internal Medicine | Year: 2014

Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of preventive dietary and pharmacologic management of recurrent nephrolithiasis in adults.Methods: This guideline is based on published literature on this topic that was identified using MEDLINE, the Cochrane Database of Systematic Reviews (through March 2014), Google Scholar, ClinicalTrials.gov, and Web of Science. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline include symptomatic stone recurrence, pain, urinary tract obstruction with acute renal impairment, infection, procedurerelated illness, emergency department visits, hospitalizations, quality of life, and end-stage renal disease. This guideline grades the quality of evidence and strength of recommendations using ACP's clinical practice guidelines grading system. The target audience for this guideline is all clinicians, and the target patient population is all adults with recurrent nephrolithiasis (-1 prior kidney stone episode).Recommendation 1: ACP recommends management with increased fluid intake spread throughout the day to achieve at least 2 L of urine per day to prevent recurrent nephrolithiasis. (Grade: weak recommendation, low-quality evidence).Recommendation 2: ACP recommends pharmacologic monotherapy with a thiazide diuretic, citrate, or allopurinol to prevent recurrent nephrolithiasis in patients with active disease in which increased fluid intake fails to reduce the formation of stones. (Grade: weak recommendation, moderate-quality evidence). © 2014 American College of Physicians.


News Article | November 9, 2016
Site: www.rdmag.com

Precision Fabrics was testing a synthetic silk sheet to determine if a new fabric engineered at its Vinton plant would wick away the moisture and heat of hot flashes and allow women going through menopause to sleep better. Then the sister of a corporate manager became ill with cancer and developed several bed sores. "He saw the ravage that they created, knew what we did and said, 'We have to advance this technology.' That accelerated it from menopause and overall better, deeper sleep to an application in acute health care, long-term care and home health care," said James Barry, business manager for the company's health products. Precision Fabrics partnered with Standard Textile, a global supplier of hospital linens with U.S. headquarters in Ohio, to test DermaTherapy. After 11 clinical trials at several hospitals showed incidences of pressure ulcers were reduced by 65 percent to 80 percent, the Food and Drug Administration in June certified DermaTherapy as a medical device. It's a first for a bed sheet, and it flips conventional thinking: Instead of sheets and pads protecting the mattress, they protect the patient. "It's Under Armour for your bed," Barry said. "You don't go out today and run or work out, cross train, bike or play tennis in 100 percent cotton. You play in engineered fabric, so why wouldn't you put it on your bed for all the same reasons?" What the company found during the trials is that so-called pressure ulcers aren't caused by pressure at all but rather by what happens when moisture, friction and shear of bed linens interact with skin. "There's been so much focus for decades on managing the pressure of the surface. Billions of dollars have been spent, and there are 200 surface products, mattresses and things that go on them that focus on pressure. They still put the lowest-grade cotton or poly-cotton linens on them. And that's what's touching the skin," Barry said. The short fibers of cotton break down with use and become abrasive. "Never mind an uncompromised behind, but when you put an 85-year-old with skin issues on them and you add moisture and friction, it gets sticky and creates torque and shear. That's what causes the beginning of pressure ulcers and other skin issues," he said. The Centers for Medicare and Medicaid Services estimate that hospital-acquired pressure ulcers add about $11 billion to the nation's health care bill each year. CMS will not reimburse hospitals for treating bed sores since they are considered avoidable. These wounds generally occur on patients who are in frail health and can lead to rapid decline and death. Initially, Precision Fabric didn't know that linens could cause bed sores. "We set out seven or eight years ago to develop a product that would be incredibly kind to the skin and that would manage the moisture and friction and the shear," Barry said. "We learned that after we started doing clinical trials. It's less about the pressure. We put these linens on all different types of surfaces. No matter what the pressure, ulcers went down. Through 11 clinical trials, we showed the surface of the mattress is a lot less important than what touches the skin." The patented fabric has carbon channels and antimicrobial characteristics to reduce odor and static, and a treatment to repel stains. Though the company cannot claim reduction in infection rates, as it has not conducted clinical trials and gained FDA certification for that component, "hospitals have told us the bad stuff — MRSA, E. coli, C. diff — has gone down, and at the end of the day, it smells better, which is a huge deal, especially in long-term care," he said. With the FDA approval, the company hopes that it can change the mindset of hospital and nursing home managers to view bed sheets as part of patients' treatment rather than as housekeeping items. "We are just at the beginning of the beginning," Barry said. Precision Fabrics has been talking with Carilion Clinic but has yet to get into the local hospital system. The company's headquarters in Greensboro, North Carolina, turned to Moses Cone Hospital for its first trials in the renal unit and then the surgical intensive care unit. It would like to foster a similar arrangement with Carilion. "We're always interested in improving the care our patients receive, so those conversations continue, particularly in light of the FDA clearance a few weeks ago," said Carilion spokesman Chris Turnbull. Vinton plant manager Mike Maust said he's looking forward to other hospitals and long-term care centers seeing the benefits of the fabric and is preparing for a run on sheets. "We'd love to employ 500 people right here in Vinton," he said, adding that the company has about 28 acres to build upon. The 330,000-square-foot plant operates three shifts with 185 employees. It makes about 50 million square yards of engineered woven fabric each year, much of it for parachutes and the aerospace industry. On a product wall is a photo of the U.S. Airways flight dubbed the "Miracle on the Hudson," the subject of the recent movie "Sully." The fabric for the inflatable chute was made in Vinton, Maust said. DermaTherapy also is sold online directly to consumers, with twin sets running $109 and king size $149. The company also makes a sports line that it says some professional and college athletes use as a recovery rest tool, since the sheets promote a deeper sleep with less waking. Barry said he packs at least a pillowcase for himself when he stays in hotels.


Montgomery J.B.,Carilion Clinic
Journal for healthcare quality : official publication of the National Association for Healthcare Quality | Year: 2013

Because the economic crisis in the United States continues to have an impact on healthcare organizations, industry leaders must optimize their decision making. Discrete-event computer simulation is a quality tool with a demonstrated track record of improving the precision of analysis for process redesign. However, the use of simulation to consolidate practices and design efficiencies into an unfinished medical office building was a unique task. A discrete-event computer simulation package was used to model the operations and forecast future results for four orthopedic surgery practices. The scenarios were created to allow an evaluation of the impact of process change on the output variables of exam room utilization, patient queue size, and staff utilization. The model helped with decisions regarding space allocation and efficient exam room use by demonstrating the impact of process changes in patient queues at check-in/out, x-ray, and cast room locations when compared to the status quo model. The analysis impacted decisions on facility layout, patient flow, and staff functions in this newly consolidated practice. Simulation was found to be a useful tool for process redesign and decision making even prior to building occupancy. © 2011 National Association for Healthcare Quality.


News Article | February 28, 2017
Site: www.prnewswire.com

WASHINGTON, Feb. 28, 2017 /PRNewswire/ -- Evolent Health, a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, announced today its partnership with Carilion Clinic. The partnership will guide the development and exe...

Loading Carilion Clinic collaborators
Loading Carilion Clinic collaborators